Neurocare has received the US Food and Drug Administration (FDA) clearance for its Apollo Transcranial Magnetic Stimulation (TMS) devices to treat obsessive-compulsive disorder (OCD).
Apollo TMS Therapy, already approved in the US for Major Depressive Disorder (MDD), uses a magnetic field to stimulate brain pathways.
The systems are designed to support advanced treatment protocols, offering symptom relief and improving the quality of life for OCD patients.
According to Neurocare, the FDA approval provides OCD patients in the US with a non-invasive, drug-free alternative to traditional therapies.
The traditional therapies like cognitive behavioural therapy and SSRIs are often associated with high drop-out rates and limited success.
The new FDA clearance offers clinicians a valuable tool to help manage these symptoms more effectively, said the Germany-based company.
Since 2021, Neurocare has installed over 300 Apollo systems in US clinics and institutions primarily for MDD treatment, which are now available for OCD.
Furthermore, several insurers are offering coverage for TMS Therapy for MDD, with some beginning to extend the coverage to OCD.
Neurocare North American operations managing director Stanford Miller said: “With this new FDA clearance, we can help more people living with OCD access a safe and effective, non-drug treatment option that can make a real difference in their daily lives.
“Our Apollo TMS Therapy technology sets a new standard of care in the treatment of OCD, empowering clinicians to deliver the highest level of patient care.”
Neurocare has developed a comprehensive mental health platform that integrates psychotherapy, neuromodulation, and other innovative methods.
The platform supports clinicians in creating personalised therapy plans that enhance self-regulation and resilience.
The company’s technology is used in its clinics across Australia, the Netherlands, the UK, and the US, as well as in third-party clinics.
